share_log

華領醫藥-B：股份發行人的證券變動月報表

HUA MEDICINE-B: Monthly Return of Equity Issuer on Movements in Securities

香港交易所 ·  Feb 6 03:30
Summary by Moomoo AI
華領醫藥（股份代號：02552.HK）於2024年2月6日向香港交易及結算所有限公司提交了最新的證券變動月報表，涵蓋截至2024年1月31日的情況。報告顯示，公司的法定/註冊股本及已發行股份在本月內均無變動，維持在2,000,000,000股普通股，每股面值0.001美元，總股本為2,000,000美元。此外，根據公司的股份期權計劃，本月底結存的股份期權數量為53,797,568，本月內無新增股份。公司確認，所有證券的發行均已獲得董事會的正式授權，並符合香港聯合交易所有限公司證券上市規則的相關要求。
華領醫藥（股份代號：02552.HK）於2024年2月6日向香港交易及結算所有限公司提交了最新的證券變動月報表，涵蓋截至2024年1月31日的情況。報告顯示，公司的法定/註冊股本及已發行股份在本月內均無變動，維持在2,000,000,000股普通股，每股面值0.001美元，總股本為2,000,000美元。此外，根據公司的股份期權計劃，本月底結存的股份期權數量為53,797,568，本月內無新增股份。公司確認，所有證券的發行均已獲得董事會的正式授權，並符合香港聯合交易所有限公司證券上市規則的相關要求。
HUA LIN PHARMACEUTICALS (STOCK CODE: 02552.HK) FILED ITS LATEST MONTHLY SECURITIES FLUCTUATION REPORT WITH HONG KONG TRADING AND SETTLEMENT LIMITED ON 6 FEBRUARY 2024, COVERING THE SITUATION AS OF 31 JANUARY 2024. The report shows that the company's regulary/registered share capital and issued shares remained unchanged during the month at 2,000,000,000 shares of ordinary shares with a face value of $0.001 per share and a total share capital of $2,000,000. In addition, under the Company's stock option plan, the number of stock options outstanding at the end of the month was 53,797,568, with no new shares added during the month. The Company confirms that all issuance of securities has been formally authorized by the Board of Directors and complies with the relevant requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
HUA LIN PHARMACEUTICALS (STOCK CODE: 02552.HK) FILED ITS LATEST MONTHLY SECURITIES FLUCTUATION REPORT WITH HONG KONG TRADING AND SETTLEMENT LIMITED ON 6 FEBRUARY 2024, COVERING THE SITUATION AS OF 31 JANUARY 2024. The report shows that the company's regulary/registered share capital and issued shares remained unchanged during the month at 2,000,000,000 shares of ordinary shares with a face value of $0.001 per share and a total share capital of $2,000,000. In addition, under the Company's stock option plan, the number of stock options outstanding at the end of the month was 53,797,568, with no new shares added during the month. The Company confirms that all issuance of securities has been formally authorized by the Board of Directors and complies with the relevant requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more